Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025)
Iovance Biotherapeutics (IOVA) posted quarterly Raw Materials of $37.9 million for Q1 2025, up 581.14% year-over-year from $5.6 million in Q1 2024, and up 36.65% quarter-over-quarter from $27.7 million in Q4 2024.
Iovance Biotherapeutics (IOVA) Raw Materials (2024 - 2025) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Raw Materials for 2 consecutive years, with $37.9 million the latest figure, recorded in Q1 2025.
- In Q1 2025, Raw Materials rose 581.14% year-over-year to $37.9 million; the TTM figure through Mar 2025 stood at $37.9 million (up 581.14% YoY), while the FY2024 annual figure was $27.7 million, changed N/A from the prior year.
- Raw Materials climbed to $37.9 million in Q1 2025 per IOVA's latest filing, from $27.7 million in the prior quarter.
- Across five years, Raw Materials topped out at $37.9 million in Q1 2025 and bottomed at $5.6 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 37.91 Mn |
| Dec 31, 2024 | 27.74 Mn |
| Mar 31, 2024 | 5.57 Mn |